Search Results

There are 300466 results for: content related to: Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?

  1. Clinical Pharmacology of Rasagiline: A Novel, Second-Generation Propargylamine for the Treatment of Parkinson Disease

    The Journal of Clinical Pharmacology

    Volume 45, Issue 8, August 2005, Pages: 878–894, Dr Jack J. Chen and Dr David M. Swope

    Article first published online : 19 MAR 2013, DOI: 10.1177/0091270005277935

  2. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 27, Issue S1, June 2012, Pages: S1–S523,

    Article first published online : 19 JUN 2012, DOI: 10.1002/mds.25051

  3. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?

    Movement Disorders

    Volume 23, Issue 6, 30 April 2008, Pages: 784–789, Carl E. Clarke

    Article first published online : 3 JAN 2008, DOI: 10.1002/mds.21918

  4. Monoamine Oxidase-B Inhibition in the Treatment of Parkinson's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 27, Issue 12P2, December 2007, Pages: 174S–185S, Dr. Hubert H. Fernandez and Dr. Jack J. Chen

    Article first published online : 6 JAN 2012, DOI: 10.1592/phco.27.12part2.174S

  5. Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO-B) Inhibitor Rasagiline

    The Journal of Clinical Pharmacology

    Volume 50, Issue 12, December 2010, Pages: 1420–1428, Tamar Goren, Liat Adar, Nissim Sasson and Yoni M. Weiss

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270010369674

  6. Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline

    Movement Disorders

    Volume 26, Issue 13, November 2011, Pages: 2316–2323, Peter Jenner and J. William Langston

    Article first published online : 23 SEP 2011, DOI: 10.1002/mds.23926

  7. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

    Movement Disorders

    Volume 24, Issue 4, 15 March 2009, Pages: 564–573, Robert A. Hauser, Mark F. Lew, Howard I. Hurtig, William G. Ondo, Joanne Wojcieszek and Cheryl J. Fitzer-Attas

    Article first published online : 11 DEC 2008, DOI: 10.1002/mds.22402

  8. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

    Movement Disorders

    Volume 23, Issue 15, 15 November 2008, Pages: 2194–2201, C. Warren Olanow, Robert A. Hauser, Joseph Jankovic, William Langston, Anthony Lang, Werner Poewe, Eduardo Tolosa, Fabrizio Stocchi, Eldad Melamed, Eli Eyal and Olivier Rascol

    Article first published online : 19 OCT 2008, DOI: 10.1002/mds.22218

  9. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

    Movement Disorders

    Volume 26, Issue S3, October 2011, Pages: S2–S41, Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz and Cristina Sampaio

    Article first published online : 21 OCT 2011, DOI: 10.1002/mds.23829

  10. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease

    International Journal of Clinical Practice

    Volume 60, Issue 2, February 2006, Pages: 215–221, F. Stocchi

    Article first published online : 1 FEB 2006, DOI: 10.1111/j.1742-1241.2006.00806.x

  11. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson’s disease

    European Journal of Neurology

    Volume 19, Issue 2, February 2012, Pages: 258–264, E. Tolosa and M. B. Stern

    Article first published online : 5 AUG 2011, DOI: 10.1111/j.1468-1331.2011.03484.x

  12. The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge?

    The Journal of Clinical Pharmacology

    Volume 52, Issue 5, May 2012, Pages: 620–628, Dr Jack J. Chen and Dr Jayne R. Wilkinson

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270011406279

  13. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 29, Issue S1, May 2014, Pages: S1–S571,

    Article first published online : 6 JUN 2014, DOI: 10.1002/mds.25914

  14. You have free access to this content
    Neuroprotection by Rasagiline: A New Therapeutic Approach to Parkinson's Disease?

    CNS Drug Reviews

    Volume 11, Issue 2, March 2005, Pages: 183–194, Fabio Blandini

    Article first published online : 7 JUN 2006, DOI: 10.1111/j.1527-3458.2005.tb00269.x

  15. 2nd World Parkinson Congress Abstracts

    Movement Disorders

    Volume 25, Issue S3, 15 September 2010, Pages: S569–S717,

    Article first published online : 9 SEP 2010, DOI: 10.1002/mds.23386

    Corrected by:

    Erratum: Erratum

    Vol. 25, Issue 15, 2694, Article first published online: 10 NOV 2010

  16. Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Rasagiline: A Potent, Selective, and Irreversible Monoamine Oxidase Type B Inhibitor

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 24, Issue 10, October 2004, Pages: 1295–1305, Dr. John J. Thébault, Dr. Michel Guillaume and Dr. Ruth Levy

    Article first published online : 16 JAN 2012, DOI: 10.1592/phco.24.14.1295.43156

  17. Abstracts of The Movement Disorder Society's Twelfth International Congress of Parkinson's Disease and Movement Disorders

    Movement Disorders

    Volume 23, Issue S1, 15 May 2008, Pages: S1–S422,

    Article first published online : 28 MAY 2008, DOI: 10.1002/mds.22133

  18. Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (STACCATO)

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 34, Issue 12, December 2014, Pages: 1250–1258, Michel Panisset, Jack J. Chen, Sean H. Rhyee, Jill Conner, Julie Mathena and the STACCATO study investigators

    Article first published online : 14 OCT 2014, DOI: 10.1002/phar.1500

  19. Poster Session 3

    Movement Disorders

    Volume 21, Issue S15, September 2006, Pages: S517–S613,

    Article first published online : 20 SEP 2006, DOI: 10.1002/mds.21248

  20. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation

    Journal of Neuroscience Research

    Volume 58, Issue 3, 1 November 1999, Pages: 456–463, Saleh Abu-Raya, Eran Blaugrund, Victoria Trembovler, Eugenia Shilderman-Bloch, Esther Shohami and Philip Lazarovici

    Article first published online : 11 OCT 1999, DOI: 10.1002/(SICI)1097-4547(19991101)58:3<456::AID-JNR12>3.0.CO;2-S